AKRO
Akero Therapeutics Inc
NASDAQ: AKRO · HEALTHCARE · BIOTECHNOLOGY
$54.65
+0.00% today
Updated 2025-12-09
Market cap
$4.50B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.75
Dividend yield
—
52W range
$32 – $57
Volume
2.9M
Akero Therapeutics Inc (AKRO) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$54.65
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.